Relugolix Shows Benefit in Uterine Fibroid Late-Stage Study

Pfizer and Myovant Sciences have announced that their phase 3 trial evaluating an investigational treatment for uterine fibroids, a once-daily combination of relugolix with estradiol and norethindrone acetate, was successful in meeting its primary endpoint.

Roughly three-quarters of women enrolled in the trial saw a 50 percent or greater reduction from baseline in menstrual blood loss volume during the last 35 days of treatment.

The results “offer strong evidence” that the combination therapy could be an important new oral treatment for patients with uterine fibroids, said James Rusnak, Pfizer’s chief development officer, internal medicine and hospital, global product development.